NORTH CHICAGO, Ill., Jan. 20, 2026 /PRNewswire/ — Rosalind Franklin University (RFU) announced today that Hongkyun Kim, PhD, professor of cell biology and anatomyNORTH CHICAGO, Ill., Jan. 20, 2026 /PRNewswire/ — Rosalind Franklin University (RFU) announced today that Hongkyun Kim, PhD, professor of cell biology and anatomy

Rosalind Franklin University Researcher Awarded $1.9M NIH Grant for Neurological Disease Research

NORTH CHICAGO, Ill., Jan. 20, 2026 /PRNewswire/ — Rosalind Franklin University (RFU) announced today that Hongkyun Kim, PhD, professor of cell biology and anatomy in RFU’s Center for Cancer Cell Biology, Immunology and Infection, was awarded a 5-year NIH grant from the National Institute of Neurological Disorders and Stroke for a total of $1,911,417. The grant will fund Dr. Kim’s research on “molecular and cellular regulation of CaV2 voltage-gated calcium channels.”

Dr. Kim’s research addresses the dysregulation of human proteins linked to a wide range of diseases. He is looking at a key protein in synaptic transmission: the voltage-gated calcium channel. These channels at the synapse determine how strongly nerve cells communicate with each other. This research is vital because abnormalities in channel function or abundance are often the underlying cause of neurological disorders, such as epilepsies, migraines and pain.

Dr. Kim joined RFU in 2008 from UCSF’s Ernest Gallo Clinic and Research Center, where he completed his post-doctoral training and afterward became an associate researcher. His research focus has been the genetic and genomic approaches to understand the pathogenesis mechanisms of neurological and neuromuscular diseases.

“Our favorite protein among proteins involved in synaptic transmission is the CaV2 voltage-gated calcium channel,” Dr. Kim said. “The voltage-gated calcium channel is critical for neurotransmitter release at the synapse of neurons. Using C. elegans as a model organism, we intend to identify and determine molecular components responsible for the abundance of these calcium channels.”

“Dr. Kim has amassed an impressive body of work in this field of neurological disorders,” said Joseph DiMario, PhD, RFU’s executive vice president for research. “This new NIH award is a recognition of his expertise in this domain and will further expand the understanding of this critical channel in these disease pathologies.”

About RFU

Rosalind Franklin University of Medicine and Science is committed to serving humanity through the interprofessional education of health and biomedical professionals and the discovery of knowledge dedicated to improving wellness. The university embodies the spirit of inquiry and excellence modeled by its namesake, Dr. Rosalind Franklin, whose Photo 51 was crucial to solving the structure of DNA. Recognized for its research in areas including neuroscience, brain-related diseases, inherited disorders, diabetes, obesity, and gait and balance, RFU encompasses the Chicago Medical School, College of Health Professions, College of Nursing, College of Pharmacy, School of Graduate and Postdoctoral Studies, and the Dr. William M. Scholl College of Podiatric Medicine. Learn more at rosalindfranklin.edu.

Media Contact:
Office of Marketing and Communications
media@rosalindfranklin.edu

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rosalind-franklin-university-researcher-awarded-1-9m-nih-grant-for-neurological-disease-research-302665688.html

SOURCE Rosalind Franklin University of Medicine and Science

Market Opportunity
Ucan fix life in1day Logo
Ucan fix life in1day Price(1)
$0.001303
$0.001303$0.001303
+0.92%
USD
Ucan fix life in1day (1) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin Withdraws 16,384 ETH to Fund Open-Source Technology and Privacy Projects

Vitalik Buterin Withdraws 16,384 ETH to Fund Open-Source Technology and Privacy Projects

TLDR: Buterin withdrew 16,384 ETH to personally fund open-source projects as Ethereum Foundation reduces spending.  The initiative supports secure hardware, privacy
Share
Blockonomi2026/01/30 16:39
What is the most promising crypto right now? A practical checklist

What is the most promising crypto right now? A practical checklist

Crypto interest often spikes after headlines. This guide helps everyday readers turn curiosity into repeatable checks that limit obvious execution risks. We focus
Share
Coinstats2026/01/30 15:52
Inside Upexi’s SOL play: staking yield and locked token deals

Inside Upexi’s SOL play: staking yield and locked token deals

The post Inside Upexi’s SOL play: staking yield and locked token deals appeared on BitcoinEthereumNews.com. Upexi is the largest public company holding Solana tokens and uses a SOL strategy to build its holdings and generate additional revenue through staking. In an interview with crypto.news, Upexi CEO Allan Marshall explains why the company executed a large equity private placement to build a crypto treasury, citing MicroStrategy’s playbook and a more accommodating U.S. policy backdrop. Summary Upexi is the largest public holder of Solana, using equity raises to build a SOL treasury and earn staking yield. Upexi CEO Allan Marshall spoke with crypto.news in an interview. Corporate strategy focuses on accretive issuances, staking, and discounted locked SOL purchases, not venture investing. Upexi markets itself as a “new institutional gateway to Solana’s (SOL) speed, scale, and rapidly growing ecosystem.” But it isn’t alone, as it joins a handful of rival companies also building Solana treasuries, while dozens of other public entities are focusing on other coins. Speaking to crypto.news, Marshall discusses strategy and market perception. He notes that Upexi is focused on accretive capital raises, staking, and discounted, locked SOL purchases rather than venture investing. He also discusses how the company measures progress through an “adjusted SOL per share” metric designed to remove timing and leverage effects. We also discuss the company’s risk management strategies, which include a buy-and-hold approach, no hedging, disciplined use of leverage, and custody with qualified providers. The entire interview transcript is below: crypto.news: Upexi is now the largest corporate holder of Solana with over 2 million SOL in treasury. Why did you make such a dramatic shift now? Was there something specific that happened in the past few months that gave you the confidence to commit so heavily to a crypto treasury at this time? Allan Marshall: Upexi did the first large-scale equity private placement to create an altcoin treasury, and there were…
Share
BitcoinEthereumNews2025/09/20 02:51